Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism SMO antagonists(Smoothened receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H32N6O |
InChIKeyPOERAARDVFVDLO-QGZVFWFLSA-N |
CAS Registry1204975-42-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Medulloblastoma | Phase 3 | GB | 01 Oct 2010 | |
Recurrent Medulloblastoma | Phase 3 | CH | 01 Oct 2010 | |
Recurrent Medulloblastoma | Phase 3 | US | 01 Oct 2010 | |
Recurrent Medulloblastoma | Phase 3 | NL | 01 Oct 2010 | |
Refractory Medulloblastoma | Phase 3 | CH | 01 Oct 2010 | |
Refractory Medulloblastoma | Phase 3 | GB | 01 Oct 2010 | |
Metastatic basal cell carcinoma | Phase 1 | US | 01 Oct 2010 | |
Metastatic basal cell carcinoma | Phase 1 | NL | 01 Oct 2010 | |
Refractory Medulloblastoma | Phase 1 | NL | 01 Oct 2010 | |
Refractory Medulloblastoma | Phase 1 | US | 01 Oct 2010 |